Tanimura, Keiko
Yamada, Tadaaki http://orcid.org/0000-0002-6945-281X
Okada, Koutaroh
Nakai, Kunihiro
Horinaka, Mano
Katayama, Yuki
Morimoto, Kenji
Ogura, Yuri
Takeda, Takayuki http://orcid.org/0000-0002-8375-6940
Shiotsu, Shinsuke
Ichikawa, Kosuke
Watanabe, Satoshi
Morimoto, Yoshie
Iwasaku, Masahiro
Kaneko, Yoshiko
Uchino, Junji
Taniguchi, Hirokazu http://orcid.org/0000-0003-2414-8344
Yoneda, Kazue
Matoba, Satoaki
Sakai, Toshiyuki
Uehara, Hisanori
Yano, Seiji
Kusaba, Tetsuro
Katayama, Ryohei http://orcid.org/0000-0001-7394-895X
Takayama, Koichi
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (19K08608, 20K22820, 19H03524)
Takeda Pharmaceutical Company
Takeda Science Foundation
Japan Research Foundation for Clinical Pharmacology (2018A18)
Joint Research with the Cancer Research Institute of Kanazawa University
Japan Agency for Medical Research and Development (JP20cm0106203h0005)
Article History
Received: 16 June 2021
Accepted: 16 December 2021
First Online: 18 January 2022
Competing interests
: T.Y. received commercial research grants from Pfizer, Ono Pharmaceutical, Chugai Pharmaceutical, and Takeda Pharmaceutical Company Limited. J.U. received research grants from Eli Lilly Japan K.K., AstraZeneca K.K., and Boehringer Ingelheim Japan. T.S. received research grants from Otsuka Pharmaceutical and Oncolys BioPharma, and a patent fee from JT Pharmaceutical. S.Y. obtained commercial research grants from Chugai Pharmaceutical and Boehringer-Ingelheim and has received speaking honoraria from Chugai Pharmaceutical, Boehringer-Ingelheim, Novartis, and Pfizer. R.K. received research grants from Chugai Pharmaceutical, Takeda Pharmaceutical Company Limited, Toppan Printing, and Daiichi-Sankyo. K.T. received research grants from Chugai-Roche and Ono Pharmaceutical and personal fees from AstraZeneca, Chugai-Roche, MSD-Merck, Eli Lilly, Boehringer-Ingelheim, and Daiichi-Sankyo. The remaining authors declare no competing interests.